← Back

Hainan Shuangcheng Pharmaceut

Hainan Shuangcheng Pharmaceuticals Co., Ltd. researches, develops, produces, and sells pharmaceutical injections, solid preparations, and raw materials in China and internationally. Its products target oncology and immune, alimentary canal, heart and cerebral, and vessels and metabolism areas. The company also offers injectable Bivalirudin, Eptifibatide, and Thymalfasin, Pregabalin capsules, and Memantine Hydrochloride and Pioglitazone tablets USP. Founded in 2000, it is headquartered in Haikou, the People's Republic of China.

Country
Price · split & dividend adjusted
News & notes moving 002693.CS
002693.CS

Shuangcheng Pharmaceutical Releases 2026 Interim Report with Net Profit of 13.6278 Million Yuan

Shuangcheng Pharmaceutical released its 2026 interim report on August 22, 2026. The company's total operating revenue was 117 million yuan, net profit attributable to the parent company was 13.6278 million yuan, and net cash inflow from operating activities was 20.5123 million yuan. The company's latest asset-liability ratio was 47.02%, gross margin was 55.61%, down 6.75 percentage points from the previous quarter, and latest return on equity was 3.20%. The company's diluted earnings per share was 0.03 yuan, total asset turnover was 0.14 times, and inventory turnover was 0.69 times. The company had 38,700 shareholders, and the top ten shareholders held 217 million shares, accounting for 52.40% of total share capital.
002693.CS
Jiemian·28dRead more →
002693.CS▲

Shuangcheng Pharmaceutical Expects to Turn Profitable in First Half of 2026

Shuangcheng Pharmaceutical disclosed its earnings forecast, expecting net profit attributable to shareholders of 10 million to 15 million yuan in the first half of 2026, compared with a loss of 18.4666 million yuan in the same period last year, turning from loss to profit year-on-year. Deducted non-recurring net profit is expected to be 7.5 million to 11 million yuan, compared with a loss of 21.0158 million yuan in the same period last year. Basic earnings per share are expected to be 0.0241 yuan to 0.0362 yuan. The company stated that the change in performance is mainly due to the orderly export business of its paclitaxel for injection (albumin-bound) product, with steady sales progress to US customers. The product obtained US marketing approval in May last year, and the sales period achievable in the same period last year was relatively short, leading to year-on-year revenue growth in the current period.
002693.CS ▲
中国证券报·67dRead more →
© 2026 MarketDXAsset